Last reviewed · How we verify

NCT03816553

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Completed Phase 2 Last updated 11 April 2023
What this trial tests

Phase 2 trial testing SHR-1210 in Recurrent Cervical Carcinoma in 45 participants. Completed in 31 August 2022.

Timeline
19 January 2019
Primary endpoint
30 April 2020
31 August 2022

Quick facts

Lead sponsorSun Yat-sen University
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment45
Start date19 January 2019
Primary completion30 April 2020
Estimated completion31 August 2022
Sites3 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, female only, with Recurrent Cervical Carcinoma or Metastatic Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the efficacy and safety of SHR-1210 in combination with apatinib in treating patients with metastatic, persistent, or recurrent cervical cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
    Yi M, Zheng X, Niu M, Zhu S, et al · · 2022 · cited 1018× · PMID 35062949 · DOI 10.1186/s12943-021-01489-2
  2. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.
    Yang Y, Li S, Wang Y, Zhao Y, et al · · 2022 · cited 182× · PMID 36115852 · DOI 10.1038/s41392-022-01168-8
  3. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
    Lan C, Shen J, Wang Y, Li J, et al · · 2020 · cited 164× · PMID 33052760 · DOI 10.1200/jco.20.01920
  4. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
    Wang Q, Peng H, Qi X, Wu M, et al · · 2020 · cited 114× · PMID 32728057 · DOI 10.1038/s41392-020-0199-6
  5. Recurrent or primary metastatic cervical cancer: current and future treatments.
    Gennigens C, Jerusalem G, Lapaille L, De Cuypere M, et al · · 2022 · cited 87× · PMID 36108558 · DOI 10.1016/j.esmoop.2022.100579
  6. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.
    Zhou X, Ni Y, Liang X, Lin Y, et al · · 2022 · cited 64× · PMID 36189283 · DOI 10.3389/fimmu.2022.915094
  7. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
    Peng H, He X, Wang Q. · · 2022 · cited 38× · PMID 35751489 · DOI 10.1111/aogs.14412
  8. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
    Huang X, He M, Peng H, Tong C, et al · · 2021 · cited 38× · PMID 34011535 · DOI 10.1136/jitc-2020-002223

Verify or expand the search:

Other trials of SHR-1210

Trials testing the same drug.

Other recruiting trials for Recurrent Cervical Carcinoma

Currently open trials in the same condition.

Other Sun Yat-sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03816553.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing